StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
ACRVBullishCorporate Developmentsnews
High materiality8/10

ACRV's ACR-7280 shows AML regression; IND planned for H1 2027

Oct 20, 2026, 9:02 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong preclinical efficacy and a near-term IND milestone can re-rate the stock if translation holds; biotech stocks often double as IND timelines approach but face risk if data fail to translate.

AI summary

What happened, with direct paths to the underlying reporting

Acrivon reports that ACR-7280, a CDK11 inhibitor, produced complete tumor regression in aggressive AML xenografts and was prioritized for potency and synergy with BCL-2 and menin inhibitors. IND-enabling studies are underway with an IND submission targeted for the first half of 2027, potentially de-risking the program and validating the AP3 AI-driven platform for rapid development.

  • ACRV-7280 shows complete AML tumor regression in xenografts.
  • ACR-7280 prioritized among CDK11 inhibitors for potency and synergy with BCL-2/menin inhibitors.
  • IND-enabling studies ongoing; IND submission targeted for H1 2027.
  • AP3 platform advances AI-enabled design; ACR-7280 is next development candidate.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event